Roche Manager Defends Hard Line Against Generics
This article was originally published in PharmAsia News
The managing director of Roche Scientific India defended the firm's hard-line stance in a patent suit against Cipla over the drug Tarceva (erlotinib hydrochloride). Girish Trelang acknowledged Roche was not keeping a low profile in the branded versus generic struggle. The suit is seen as a test of future court decisions on drug patent law, but Telang said Roche must defend its patents because although it pays customs duty of 32 percent in addition to developing the drug, it still charges only 15 percent more than the generic. (Click here for more
You may also be interested in...
The approval is based on the results ABRE clinical study, which showed the stent improved patency iliofemoral veins in 88% of cases with a 2% rate of major adverse events.
Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.